Skip to main content
NIH funding notice PAR-17-200

Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R41)

Closed on January 5, 2020.

Posted
March 29, 2017
Close date
January 5, 2020
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $440,876 in first-year total cost, median $220,438.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 ETTN-D (50)]2

Most frequent institutions

  1. BB MEDICAL SURGICAL, INC.1
  2. EARNANO, LLC1
Competing awards under PAR-17-200 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2019A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants1R41HD097969-01BERNSTEIN, CHRISTINA BRANDTREHAN, VIRENDER KBB MEDICAL SURGICAL, INC., CA$223,271ZRG1
2019Targeting bacteria, the innate response of the middle ear to infection, and host-pathogen interactions, using topical and transtympanic applications for the treatment of otitis media.1R41HD097038-01A1SCHACHERN, PATRICIA ANNEARNANO, LLC, MN$217,605ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-17-200: Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R41) | ScienceDex | ConductScience